Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma

Anti-programmed cell death protein 1 (PD1) antibodies are in wide use for the treatment of various cancers. PD1 antibody-based immunotherapy, co-administration of nivolumab and ipilimumab, is one of the optimal immunotherapies, especially in advanced melanoma with high tumor mutation burden. Since t...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Front Med (Lausanne)
Main Authors: Fujimura, Taku, Sato, Yota, Tanita, Kayo, Lyu, Chunbing, Kambayashi, Yumi, Amagai, Ryo, Otsuka, Atsushi, Fujisawa, Yasuhiro, Yoshino, Koji, Matsushita, Shigeto, Uchi, Hiroshi, Yamamoto, Yuki, Hata, Hiroo, Funakoshi, Takeru, Nonomura, Yumi, Tanaka, Ryota, Okuhira, Hisako, Wada, Naoko, Hashimoto, Akira, Aiba, Setsuya
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2019
נושאים:
Medicine
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6497728/
https://ncbi.nlm.nih.gov/pubmed/31080803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2019.00086
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים